IDEXX Laboratories Expects 2024 Revenue Of $3.865B-$3.89B Versus Prior Guidance Of $3.885B-$3.945B And Consensus Of $3.92B
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories has adjusted its 2024 revenue guidance to $3.865B-$3.89B, down from previous estimates, due to macroeconomic and sector challenges affecting U.S. veterinary clinics. The company expects revenue growth of 5.5%-6.2% as reported and 5.3%-6.0% organic.
October 31, 2024 | 10:43 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IDEXX Laboratories has lowered its 2024 revenue guidance due to macroeconomic and sector challenges impacting U.S. veterinary clinics. The new guidance is $3.865B-$3.89B, with expected growth of 5.5%-6.2% as reported and 5.3%-6.0% organic.
IDEXX Laboratories' reduction in revenue guidance suggests potential challenges in the market, particularly in the U.S. veterinary sector. This could lead to a negative short-term impact on the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100